DBV Technologies S.A.'s SEC filings document a foreign issuer reporting framework for ordinary shares and American Depositary Shares. Form 8-K reports furnish financial results and business highlights, disclose registered securities, and record material governance and compensation actions.
Proxy materials for DBV Technologies S.A. cover shareholder voting matters, board authorization, compensation committee recommendations and equity award authority under French corporate law. The filings also identify ADS terms in which each American Depositary Share represents five ordinary shares, with the ADSs registered on Nasdaq under DBVT.
DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.
DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.
Adage Capital Management and associated reporting persons report beneficial ownership of 22,272,884 Ordinary Shares of DBV Technologies S.A., representing 7.31% of the class based on March 25, 2026 outstanding share data. The percentage is calculated using 296,042,447 Ordinary Shares outstanding and assumes conversion of Ordinary Shares issuable upon conversion of shares of convertible preferred stock issuable upon exercise of warrants.
The filing names Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as reporting persons and discloses shared voting and dispositive power of 22,272,884 shares. Each ADS represents 5 Ordinary Shares under the CUSIP 23306J309.
Adage Capital Management and associated reporting persons report beneficial ownership of 22,272,884 Ordinary Shares of DBV Technologies S.A., representing 7.31% of the class based on March 25, 2026 outstanding share data. The percentage is calculated using 296,042,447 Ordinary Shares outstanding and assumes conversion of Ordinary Shares issuable upon conversion of shares of convertible preferred stock issuable upon exercise of warrants.
The filing names Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as reporting persons and discloses shared voting and dispositive power of 22,272,884 shares. Each ADS represents 5 Ordinary Shares under the CUSIP 23306J309.
DBV TECHNOLOGIES S.A. reported that Artisan Partners entities jointly beneficially own 2,219,386 American Depositary Shares, equal to 3.7% of the class. The filing states this stake is based on 59,208,489 shares outstanding as of 03/25/2026 and lists shared voting and dispositive powers.
The Schedule 13G/A is a joint filing by Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership and includes a joint filing agreement dated 05/13/2026.
DBV TECHNOLOGIES S.A. reported that Artisan Partners entities jointly beneficially own 2,219,386 American Depositary Shares, equal to 3.7% of the class. The filing states this stake is based on 59,208,489 shares outstanding as of 03/25/2026 and lists shared voting and dispositive powers.
The Schedule 13G/A is a joint filing by Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership and includes a joint filing agreement dated 05/13/2026.
DBV Technologies S.A. ownership disclosure: Vivo Opportunity entities report beneficial ownership positions in the issuer's Ordinary Shares represented by ADSs. Vivo Opportunity, LLC and its affiliated Delaware partnership report 11,820,005 Ordinary Shares (represented by 2,364,001 ADSs), equal to 4.0% of shares.
Related Cayman entities report 1,517,840 Ordinary Shares (represented by 303,568 ADSs), equal to 0.5%. The percent calculations use 296,042,447 Ordinary Shares outstanding as of April 30, 2026.
DBV Technologies S.A. ownership disclosure: Vivo Opportunity entities report beneficial ownership positions in the issuer's Ordinary Shares represented by ADSs. Vivo Opportunity, LLC and its affiliated Delaware partnership report 11,820,005 Ordinary Shares (represented by 2,364,001 ADSs), equal to 4.0% of shares.
Related Cayman entities report 1,517,840 Ordinary Shares (represented by 303,568 ADSs), equal to 0.5%. The percent calculations use 296,042,447 Ordinary Shares outstanding as of April 30, 2026.
DBV Technologies, a clinical-stage biopharma company focused on food allergies, highlights a defining year led by positive topline Phase 3 VITESSE results for the VIASKIN® Peanut Patch in children aged 4 to 7 years. These data support a planned Biologics License Application submission in the United States in the first half of the year and underpin preparations for potential commercialization.
The company is also advancing the COMFORT Toddlers safety trial in children aged 1 to 3 years and THRIVE, a first-of-its-kind study in infants aged 6 to 12 months. DBV reports raising $386.2 million in capital between March 2025 and January 2026, providing funding into the second quarter of 2027, including the potential U.S. launch of the VIASKIN Peanut Patch.
The proxy statement convenes the 2026 Annual Combined General Meeting on June 3, 2026 in Châtillon, France, with 40 resolutions covering approval of 2025 financial statements, director elections and compensation, share buyback and cancellation authority, extensive capital-raising and merger/de-merger authorizations, equity incentive plans, and bylaw amendments such as setting the CEO age limit at 70 years.
DBV Technologies, a clinical-stage biopharma company focused on food allergies, highlights a defining year led by positive topline Phase 3 VITESSE results for the VIASKIN® Peanut Patch in children aged 4 to 7 years. These data support a planned Biologics License Application submission in the United States in the first half of the year and underpin preparations for potential commercialization.
The company is also advancing the COMFORT Toddlers safety trial in children aged 1 to 3 years and THRIVE, a first-of-its-kind study in infants aged 6 to 12 months. DBV reports raising $386.2 million in capital between March 2025 and January 2026, providing funding into the second quarter of 2027, including the potential U.S. launch of the VIASKIN Peanut Patch.
The proxy statement convenes the 2026 Annual Combined General Meeting on June 3, 2026 in Châtillon, France, with 40 resolutions covering approval of 2025 financial statements, director elections and compensation, share buyback and cancellation authority, extensive capital-raising and merger/de-merger authorizations, equity incentive plans, and bylaw amendments such as setting the CEO age limit at 70 years.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies S.A. Schedule 13G/A amendment shows institutional holders led by Invus entities reporting beneficial ownership stakes in the issuer. Invus Public Equities beneficially held 17,997,870 ordinary shares as of March 31, 2026, representing 6.1% of the class. The filing states 296,042,447 shares outstanding as of March 25, 2026 (source: the issuer's Form 10-K).
The filing aggregates related parties and control links: Invus PE Advisors, Global Management, Siren, Avicenna entities, Ulys, and Raymond Debbane are disclosed as reporting persons or controlling entities; Mr. Debbane is the signing reporting person.
DBV Technologies S.A. Schedule 13G/A amendment shows institutional holders led by Invus entities reporting beneficial ownership stakes in the issuer. Invus Public Equities beneficially held 17,997,870 ordinary shares as of March 31, 2026, representing 6.1% of the class. The filing states 296,042,447 shares outstanding as of March 25, 2026 (source: the issuer's Form 10-K).
The filing aggregates related parties and control links: Invus PE Advisors, Global Management, Siren, Avicenna entities, Ulys, and Raymond Debbane are disclosed as reporting persons or controlling entities; Mr. Debbane is the signing reporting person.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.
DBV Technologies S.A. reported a larger net loss as it ramps up development and commercial preparation for its Viaskin Peanut patch. For the three months ended March 31, 2026, net loss widened to $47.6 million from $27.1 million a year earlier, driven by a sharp increase in operating expenses.
Research and development spending rose to $33.4 million, sales and marketing to $4.8 million, and general and administrative costs to $10.5 million, reflecting expanded clinical activity, pre-commercial inventory build, and build‑out of U.S. commercial and corporate infrastructure. There was still no product revenue; operating income of $0.9 million came mainly from the French research tax credit.
Following a 2025 PIPE financing and warrant exercises, DBV ended the quarter with $229.2 million in cash and cash equivalents, up from $194.2 million at year‑end 2025. Management estimates this cash should fund operations into the second quarter of 2027, assuming current plans focused on Viaskin Peanut, although faster spending or new programs could shorten that runway.
DBV Technologies S.A. reported a larger net loss as it ramps up development and commercial preparation for its Viaskin Peanut patch. For the three months ended March 31, 2026, net loss widened to $47.6 million from $27.1 million a year earlier, driven by a sharp increase in operating expenses.
Research and development spending rose to $33.4 million, sales and marketing to $4.8 million, and general and administrative costs to $10.5 million, reflecting expanded clinical activity, pre-commercial inventory build, and build‑out of U.S. commercial and corporate infrastructure. There was still no product revenue; operating income of $0.9 million came mainly from the French research tax credit.
Following a 2025 PIPE financing and warrant exercises, DBV ended the quarter with $229.2 million in cash and cash equivalents, up from $194.2 million at year‑end 2025. Management estimates this cash should fund operations into the second quarter of 2027, assuming current plans focused on Viaskin Peanut, although faster spending or new programs could shorten that runway.
DBV Technologies S.A. files an amended annual report to add detailed Part III disclosures on governance, executive compensation, ownership and related-party transactions. The filing describes a 10‑member board with nine directors independent under Nasdaq rules and gender balance requirements under French law.
As of April 15, 2026, DBV had 296,042,447 ordinary shares outstanding and a public float valued at $250.9 million as of June 30, 2025. The company reports 2025 CEO compensation of $3.36 million, including salary, bonus and equity awards, and outlines its performance‑based pay philosophy and severance terms.
The document also details equity plans with 17.8 million awards outstanding and 17.7 million shares available, large April 2025 PIPE financing generating $125.5 million plus $195.2 million from January 2026 warrant exercises, and the holdings of major shareholders such as Baker Bros., Suvretta, MPM BioImpact and Janus.
DBV Technologies S.A. files an amended annual report to add detailed Part III disclosures on governance, executive compensation, ownership and related-party transactions. The filing describes a 10‑member board with nine directors independent under Nasdaq rules and gender balance requirements under French law.
As of April 15, 2026, DBV had 296,042,447 ordinary shares outstanding and a public float valued at $250.9 million as of June 30, 2025. The company reports 2025 CEO compensation of $3.36 million, including salary, bonus and equity awards, and outlines its performance‑based pay philosophy and severance terms.
The document also details equity plans with 17.8 million awards outstanding and 17.7 million shares available, large April 2025 PIPE financing generating $125.5 million plus $195.2 million from January 2026 warrant exercises, and the holdings of major shareholders such as Baker Bros., Suvretta, MPM BioImpact and Janus.